Nanosmearing due to process shear – Influence on powder and tablet properties

Transient Temperature Monitoring of Pharmaceutical Tablets During Compaction Using Infrared Thermography

Manufacturing of pharmaceutical tablets from powders is always accompanied by the conversion of irreversible mechanical work of compaction into heat. The heat is generated due to friction between powder particles, particles and the die wall, plastic deformation of particles, bonding, and other irreversible processes. The resulting temperature increase potentially might have significant effects on a tablet's mechanical properties, disintegration time, and drug release. In the present work, we show that using infrared thermography as a nondestructive and noncontact process analytical technology (PAT) tool to measure the tablet's rate of cooling, in contrast to the temperature evolution, can be directly related to the tablet's thermal diffusivity. Results show the potential capabilities of this technique to discriminate and toward predicting tensile strength of tablets between same formulations produced at same compaction force but experienced different process shear conditions. Correlation of the tablet's tensile strength, relative density, and rate of cooling at regular regime with respect to different process shear is also discussed.

Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets

Modern drug product development is expected to follow quality-by-design (QbD) paradigm. At the same time, although there are several issue-specific examples in the literature that demonstrate the application of QbD principles, a holistic demonstration of the application of QbD principles to drug product development and control strategy, is lacking. This article provides an integrated case study on the systematic application of QbD to product development and demonstrates the implementation of QbD concepts in the different aspects of product and process design for brivanib alaninate film-coated tablets. Using a risk-based approach, the strategy for development entailed identification of product critical quality attributes (CQAs), assessment of risks to the CQAs, and performing experiments to understand and mitigate identified risks. Quality risk assessments and design of experiments were performed to understand the quality of the input raw materials required for a robust formulation and the impact of manufacturing process parameters on CQAs. In addition to the material property and process parameter controls, the proposed control strategy includes use of process analytical technology and conventional analytical tests to control in-process material attributes and ensure quality of the final product.